In Survivorship, Patricia Smith Looks to Help Others 

Patricia Smith’s experience with cancer will stay with her for the rest of her life. “Walking through deep waters changes you,” she says. “You’re still the same person, but you’re different.”   In 2009, Smith was diagnosed with B-cell diffuse lymphoma after she experienced weeks of fatigue and found a lump under her right arm. She … Read more

Bispecific Antibody Therapy for Lymphoma: What You Need to Know   

Bispecific antibody therapies are a type of immunotherapy for patients with B-cell non-Hodgkin lymphoma. These therapies provide a valuable new option for patients.  There are many standard therapies that are monoclonal antibodies. These therapies treat cancer by binding to a marker on cancer cells and rallying the immune system to destroy them.  Bispecific antibodies are … Read more

BCL2 Inhibitors: What’s the Latest Research?

BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia … Read more

A Patient-Doctor Bond Forged in Fighting Follicular Lymphoma  

Throughout the 20 years Robert Jenkins has been living with follicular lymphoma, he has been through many different treatments — from traditional chemotherapy protocols to innovative approaches like CAR T-cell therapy and bispecific antibodies. His lengthy survivorship has allowed Jenkins to benefit from new advances as they’ve emerged, and along with his wife, Lorna, one … Read more

Stem Cell Transplant and CAR T-cell Therapy: When Are They Used for Lymphoma and Multiple Myeloma?

For many patients with lymphoma or multiple myeloma, a stem cell transplant with their own stem cells (an autologous transplant) or CAR T-cell therapy can extend life significantly or even cure the disease. A variety of factors influence which of these two treatments is recommended, including:  What is the difference between stem cell transplant and … Read more

Study Identifies Markers of Response to CAR T-Cell Therapies

It may be the quintessential question about cancer therapy: why does a particular treatment work well in some patients and not others with the same disease? The question is especially relevant for immunotherapies known as CAR T-cell therapies precisely because they’re so promising. The therapies, which are made by genetically engineering a patient’s own immune … Read more

Refractory Cancer: What It Is and How It Is Treated

What does “refractory” mean medically? The word “refractory” in general use means stubborn or intractable, and in medicine it is specifically applied to disease that does not respond to treatment. Refractory cancer refers to cancer that may be resistant to initial therapy or becomes resistant during treatment. “We would consider disease refractory if doesn’t respond … Read more

Earlier Use of CAR T-Cell Therapy Approved for Relapsed Large B-cell Lymphoma Patients

Patients with large B-cell lymphoma (LBCL) who did not respond to initial treatment or relapsed within a year may now receive the CAR T-cell product axicabtagene ciloleucel (Yescarta) as a second-line therapy, following approval by the U.S. Food and Drug Administration (FDA) based on results of a recent clinical trial. Until now, the standard of … Read more

Seeking Stem Cell Transplant, Basketball Expert Makes Slam Dunk Decision

As an economist specializing in statistical analysis, Dan Rosenbaum has done everything from help the federal government use more evidence in its decision-making to assist several National Basketball Association (NBA) teams in finding and signing the best players. Research and number-crunching are his expertise, so when Rosenbaum learned he needed a life-saving stem cell transplant … Read more

What is the Role of Genetics in Lymphoma and Chronic Lymphocytic Leukemia?

Studies in large populations have shown that people who have a near relative with a form of lymphoma or chronic lymphocytic leukemia (CLL) have an increased risk of developing these diseases themselves. Both lymphoma and CLL are relatively uncommon: the average person’s lifetime risk of developing CLL, for example, is 0.57%, according to the American … Read more

What is Richter’s Syndrome and How is it Treated?

Richter’s syndrome involves the rapid transformation of chronic lymphocytic leukemia (CLL) into a significantly more aggressive form of lymphoma, usually diffuse large B-cell lymphoma (DLBCL), but occasionally Hodgkin lymphoma (HL). It arises in 2-10% of all patients with CLL and can occur at any time in the course of the disease. The goal of treatment … Read more